The Food and Drug Administration yesterday released recommendations for streamlining the approval process for medical devices that use artificial intelligence. The guidance recommends information to include in a predetermined change control plan as part of a marketing submission for a medical device using AI. The PCCP should include a description of the device's planned modifications; methods to develop, validate and implement the modifications; and an assessment of the modification's impacts. FDA will then review the PCCP within the submission to ensure the device's safety and effectiveness without needing additional marketing submissions for each modification. 

Related News Articles

Headline
The Department of Health and Human Services announced Sept. 30 that it is doubling its funding for childhood cancer research from $50 million to $100 million…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Office of Science and Technology Policy issued a request for information Sept. 26 seeking feedback on federal regulations that hinder AI development,…
Chairperson's File
Public
Although hospitals and health systems are facing many pressures and challenges, now is the time to truly transform how we care for our patients and communities…
Headline
The Joint Commission and the Coalition for Health AI released guidance Sept. 17 on the responsible use of artificial intelligence in health care, the first…
Chairperson's File
Public
With all of the challenges facing health care — a shrinking workforce population, reduced funding, new technologies and pharmaceuticals — it's no longer an…